A Study to Evaluate the Effect of Dapagliflozin on Blood Glucose Level and Renal Safety in Patients With Type 2 Diabetes

Inclusion Criteria: * Female or male aged ≥18 years and \<75 years. * History of T2DM for more than 12 months. * Inadequate glycemic control, defined as HbA1c ≥7.0% and ≤11% * Stable anti-diabetic treatment regimen * Renal impairment: CKD 3A Exclusion Criteria: * Women of childbearing potential who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period. * History of diabetic ketoacidosis or hyperosmolar nonketotic coma. * Severe uncontrolled hypertension defined as SBP ≥180 mmHg and/or Diastolic Blood Pressure (DBP) ≥110 mmHg * Any of the following Cardiovascular (CV)/Vascular Diseases within 3 months of prior to signing the consent at visit 1: Myocardial infarction, Cardiac surgery or revascularization(CABG/PTCA), Unstable angina, Unstable heart failure (HF), HF New York Heart Association (NYHA) Class IV,Transient ischemic attack (TIA) or significant cerebrovascular disease, Unstable or previously undiagnosed arrhythmia. * History of any biopsy or imaging verifying intercurrent kidney disease (such as glomerular nephritis or sign of renal artery stenosis) other than diabetic nephropathy or diabetic nephropathy with nephrosclerosis. * Significant hepatic disease, including, but not limited to, chronic active hepatitis and/or severe hepatic insufficiency. * Ongoing treatment with any SGLT2-inhibitor, GLP-1 analogue, or rapid/short acting insulins at screening. * Participation in another clinical study with an Investigational Product (IP) during the last 30 days prior to signing the consent at visit 1.